文献速递血管炎

颅内巨细胞动脉炎:一项综合性系统综述

Intracranial GCA: a comprehensive systematic review.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该系统综述检索MEDLINE、Embase和PubMed数据库,纳入102项研究报告的340例颅内巨细胞动脉炎(ICGCA)患者,总结其临床表现、检查、治疗和结局。中位年龄73.7岁(IQR 71.9-77.3),46.9%为女性;240例(70.6%)表现为卒中,67例(19.7%)仅有颅内影像学或组织学改变;最常见受累血管为椎基底动脉180例(52.9%)、颈内动脉166例(48.8%)和眼动脉49例(14.4%)。214例报告治疗,其中210例(98.1%)接受糖皮质激素;181例报告随访结局,40例(22.1%)复发、59例(32.6%)死亡。作者认为ICGCA并非罕见,可能是GCA的更严重表现,最佳治疗未知,需要结构化前瞻性评估。

要点

  • ICGCA患者中位年龄73.7岁(IQR 71.9-77.3),46.9%为女性。
  • 240例(70.6%)表现为卒中,67例(19.7%)仅有颅内影像学或组织学改变。
  • 最常见受累血管为椎基底动脉180例(52.9%)、颈内动脉166例(48.8%)、眼动脉49例(14.4%)。

核心结论

  • 作者认为ICGCA并非罕见,可能是GCA的更严重表现;ICGCA的最佳治疗未知,需要结构化前瞻性评估以更好地理解这一表现。

研究设计与样本

  • 系统综述,检索MEDLINE、Embase和PubMed数据库,纳入报告ICGCA病例的研究,研究注册于PROSPERO(42023412373)。
  • 颅内受累定义为经组织病理学或影像学确认的硬脑膜以上任何血管受累;数据采用描述性统计总结。
  • 共识别1554项研究,102项研究进入全文审查,最终纳入340例ICGCA患者。

主要发现

  • 患者中位年龄73.7岁(IQR 71.9-77.3),46.9%为女性。
  • 临床表现包括卒中240例(70.6%)和仅有颅内影像学或组织学改变67例(19.7%)。
  • 最常见受累血管为椎基底动脉180例(52.9%)、颈内动脉166例(48.8%)和眼动脉49例(14.4%)。
  • 214例报告治疗,其中210例(98.1%)接受糖皮质激素;托珠单抗、环磷酰胺和甲氨蝶呤是最常见的辅助药物。
  • 181例报告随访结局,其中复发40例(22.1%),死亡59例(32.6%)。

关键数值与推荐

  • 颅内受累定义:经组织病理学或影像学确认的硬脑膜以上任何血管受累。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出ICGCA的最佳治疗未知。
  • 原文指出需要结构化前瞻性评估以更好地理解GCA的这一表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: GCA is increasingly recognized to occur in intracranial vessels with unknown clinical ramifications. We identified all reported cases of intracranial GCA (ICGCA) in the literature to describe common presentations, investigations, treatments and outcomes. METHODS: We conducted a systematic review using MEDLINE (Medical Literature Analysis and Retrieval System Online), Embase and PubMed databases to identify studies that reported cases of ICGCA. The study was registered on a systematic review database (PROSPERO 42023412373). We defined intracranial involvement as any vessel cranial to the dura mater that was confirmed by either histopathology or imaging. Data were summarized using descriptive statistics. RESULTS: Of 1554 studies identified, 102 studies underwent full-text review. These studies included 340 patients with ICGCA. The median age was 73.7 (interquartile range [IQR] 71.9-77.3) and 46.9% patients were female. Presentations of ICGCA included stroke in 240 (70.6%) patients and isolated intracranial imaging or histologic changes in 67 (19.7%) patients. The most common vessels involved were 180 (52.9%) vertebrobasilar, 166 (48.8%) internal carotid and 49 (14.4%) ophthalmic arteries. Treatment was reported in 214 individuals. Glucocorticoids were administered to 210 (98.1%); tocilizumab, cyclophosphamide and methotrexate were the most common adjunctive medications. Of the 181 patients with reported follow-up outcomes, relapse occurred in 40 (22.1%) patients and 59 (32.6%) individuals died. CONCLUSION: Our findings suggest that ICGCA is not a rare entity and may represent a more severe manifestation of GCA. Optimal therapy for ICGCA is unknown. Structured prospective evaluation is needed to better understand this manifestation of GCA.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Patel S, Okaj I, Scott J, et al. Intracranial GCA: a comprehensive systematic review. Rheumatology (Oxford). 2025. PMID: 40131377. doi:10.1093/rheumatology/keaf162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。